Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739973 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,694
- Enrollment target
NCT00739973: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00739973 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,694 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (249% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00739973, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,694 participants
- Enrollment target
Study Summary
Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
Primary Outcome
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measure
Interventions
- DRUG Placebo
- DRUG Aliskiren 150 mg tablet
- DRUG Aliskiren 300 mg tablet
- DRUG Amlodipine 5 mg capsule
- DRUG Amlodipine 10 mg capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,694 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
What the finished NCT00739973 record still lists
NCT00739973 is an interventional study that assigns participants to a tested intervention. Its 2,694 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (249% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00739973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00739973 about?
NCT00739973 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension". Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
What is the current status of trial NCT00739973?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,694 participants. The study started on 2008-09. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00739973?
The interventions under investigation include: Placebo (DRUG), Aliskiren 150 mg tablet (DRUG), Aliskiren 300 mg tablet (DRUG), Amlodipine 5 mg capsule (DRUG), Amlodipine 10 mg capsule (DRUG).
Who is sponsoring clinical trial NCT00739973?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00739973's enrollment target sits among peer trials
2,694 84th of 2000 higher than 1,917 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05111925 · 2,690 participants
Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia